Novozymes A/S (OTCMKTS:NVZMY - Get Free Report) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 43,700 shares, a growth of 680.4% from the December 15th total of 5,600 shares. Based on an average trading volume of 44,200 shares, the days-to-cover ratio is presently 1.0 days.
Analyst Ratings Changes
Several analysts have weighed in on the company. Berenberg Bank upgraded Novozymes A/S to a "strong-buy" rating in a research report on Tuesday, September 24th. Barclays upgraded shares of Novozymes A/S to a "strong-buy" rating in a research report on Monday, November 18th. Finally, Citigroup downgraded Novozymes A/S from a "neutral" rating to a "sell" rating in a report on Thursday, October 17th.
View Our Latest Analysis on NVZMY
Novozymes A/S Stock Down 0.8 %
Shares of NVZMY traded down $0.42 during trading hours on Monday, reaching $54.95. 29,596 shares of the company traded hands, compared to its average volume of 26,614. Novozymes A/S has a 12 month low of $49.99 and a 12 month high of $72.50. The company has a market capitalization of $25.73 billion, a price-to-earnings ratio of 34.78, a price-to-earnings-growth ratio of 3.87 and a beta of 0.87. The company's fifty day moving average price is $57.95 and its two-hundred day moving average price is $62.90.
About Novozymes A/S
(
Get Free Report)
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Novozymes A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novozymes A/S wasn't on the list.
While Novozymes A/S currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
